论文部分内容阅读
目的:观察复方牛胎肝提取物片联合参芪肝康胶囊对慢性乙型肝炎患者纤维化指标及甲胎蛋白的影响。方法:纳入102例慢性乙型肝炎患者,随机分为对照组和治疗组各51例。对照组给予参芪肝康胶囊和常规的护肝治疗措施,治疗组在对照组治疗基础上增加使用复方牛胎肝提取物片,观察24周。检测2组患者治疗前后的纤维化指标及甲胎蛋白含量。结果:2组治疗后血清Ⅲ型前胶原(PCⅢ)、透明质酸(HA)、层粘连蛋白(LN)与治疗前比较,差异均有统计学意义(P<0.05)。治疗组血清PCⅢ、HA、LN与对照组比较,差异均有统计学意义(P<0.05,P<0.01)。治疗12周后,治疗组甲胎蛋白明显升高,对照组仅轻微升高,2组比较,差异有统计学意义(P<0.01)。治疗24周后,2组甲胎蛋白恢复到治疗前水平,2组比较,差异均无统计学意义(P>0.05)。结论:复方牛胎肝提取物片联合参芪肝康胶囊能降低慢性乙型肝炎患者的纤维化指标值,改善临床症状。
Objective: To observe the effects of compound bovine fetal liver extract tablets and Shenqigikang capsule on fibrosis indexes and alpha-fetoprotein in patients with chronic hepatitis B. Methods: A total of 102 patients with chronic hepatitis B were enrolled and randomly divided into control group and treatment group, 51 cases each. The control group was given Shenqigankang capsules and conventional treatment of liver protection, the treatment group in the control group based on the increase in the use of compound fetal bovine liver extract tablets, observed for 24 weeks. Two groups of patients before and after treatment of fibrosis indicators and alpha-fetoprotein content. Results: The differences of serum PCⅢ, HA and LN before treatment between the two groups were statistically significant (P <0.05). The serum PCⅢ, HA and LN in the treatment group were significantly different from those in the control group (P <0.05, P <0.01). After 12 weeks of treatment, the alpha-fetoprotein in the treatment group was significantly increased, while the control group only slightly increased. The difference between the two groups was statistically significant (P <0.01). After 24 weeks of treatment, the two groups of alpha-fetoprotein returned to their pre-treatment levels. There was no significant difference between the two groups (P> 0.05). Conclusion: Compound bovine fetal liver extract tablets combined with Shenqi Liver Capsule can reduce fibrosis index in patients with chronic hepatitis B and improve clinical symptoms.